Valcyte
Links shared publicly online about this topic
New pediatric Valcyte dosing recommendations - ONA
oncologynurseadvisor.com — “The FDA has notified healthcare professionals of new pediatric dosing recommendations for Valcyte (valganciclovir hydrochloride, from Roche) tablets and oral solution.” View full resource at oncologynurseadvisor.com
Most Recently Shared on September 15, 2010 at 6:22 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
New pediatric Valcyte dosing recommendations http://goo.gl/fb/yn93B
New pediatric Valcyte dosing recommendations - MPR
empr.com — “The FDA has notified healthcare professionals of new pediatric dosing recommendations for Valcyte (valganciclovir hydrochloride, from Roche) tablets and oral solution.” View full resource at empr.com
Most Recently Shared on September 15, 2010 at 6:37 pm By:
MPR News: New pediatric Valcyte dosing recommendations: The FDA has notified healthcare professionals of new pedia... http://bit.ly/ctBKj5
FDA issues creatinine clearance limit for Valcyte
pediatricsupersite.com — “The FDA has determined that an upper limit of 150 mL/min/1.73 m2 in creatinine clearance can prevent overdosing in certain children taking valga” View full resource at pediatricsupersite.com
Most Recently Shared on September 17, 2010 at 1:22 pm By:
Pediatric SuperSite Health Site
#FDA issues #creatinine clearance limit for #Valcyte: http://ow.ly/2FLCW
FDA Approves Valcyte(R) (valganciclovir Hydrochloride) To Prevent Cytomegalovirus (CMV) Disease In Pediatric Patients
medicalnewstoday.com — “Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has approved Valcyte(R) (valganciclovir hydrochloride) for the prevention of cytomegalovirus (CMV) dis” View full resource at medicalnewstoday.com
Most Recently Shared on September 1, 2009 at 12:51 pm By:
MNT Pediatrics News Pediatrics and Health News
FDA Approves Valcyte(R) (valganciclovir Hydrochloride) To Prevent Cytomegalovirus (CMV) Disease In Pediatric Pat.. http://bit.ly/nE5KR
FDA issues new dosing guide for children using Valcyte
fda.gov — “The U.S. Food and Drug Administration is notifying health care professionals of updated dosing recommendations for Valcyte (valganciclovir) oral tablets and solution used by children and adolescents receiving a kidney or heart transplant. The update is intended to prevent drug overdosing of children with low body weight, low body surface area, and very low serum creatinine. The revised dosing instructions now appear in the product's label.” View full resource at fda.gov
Most Recently Shared on September 15, 2010 at 5:56 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
FDA issues new dosing guide for children using Valcyte. http://ow.ly/2ELjC
Longer use of Valcyte for renal transplant patients approved - ONA
oncologynurseadvisor.com — “The FDA has approved a longer duration of therapy with Valcyte (valganciclovir, from Genentech) in adult renal transplant patients at high risk for cytomegalovirus (CMV) disease.” View full resource at oncologynurseadvisor.com
Most Recently Shared on August 11, 2010 at 2:45 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Longer use of Valcyte for renal transplant patients approved http://goo.gl/fb/EXdKT
Longer use of Valcyte for renal transplant patients approved - MPR
empr.com — “The FDA has approved a longer duration of therapy with Valcyte (valganciclovir, from Genentech) in adult renal transplant patients at high risk for cytomegalovirus (CMV) disease.” View full resource at empr.com
Most Recently Shared on August 11, 2010 at 2:49 pm By:
MPR News: Longer use of Valcyte for renal transplant patients approved: The FDA has approved a longer duration of ... http://bit.ly/dcHHe5
FDA Approves Valcyte (valganciclovir hydrochloride) to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney Transplants
drugs.com — “Valcyte (valganciclovir hydrochloride) is used to prevent cytomegalovirus (CMV) disease in pediatric kidney and heart transplant patients. Includes Valcyte side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on August 31, 2009 at 8:32 pm By:
FDA Approves Valcyte to Prevent Cytomegalovirus (CMV) Disease in Pediatric Transplant Patients - http://bit.ly/6TUXY
FDA Alert: Valcyte (valganciclovir hydrochloride) Label Change: Possible overdose in pediatric patients
drugs.com — “FDA Alert: Valcyte (valganciclovir hydrochloride) Label Change: Possible overdose in pediatric patients” View full resource at drugs.com
Most Recently Shared on September 16, 2010 at 4:14 am By:
Drugs and Devices OW OW Health
Valcyte (valganciclovir hydrochloride) Label Change: Possible overdose in pediatric patients: Audience: Transp... http://bit.ly/cHgVyF #FDA
FDA Alert: Valcyte (valganciclovir hydrochloride) Label Change: Possible overdose in pediatric patients
drugs.com — “FDA Alert: Valcyte (valganciclovir hydrochloride) Label Change: Possible overdose in pediatric patients” View full resource at drugs.com
Most Recently Shared on September 17, 2010 at 1:21 am By:
FDA Alert - Labeling Change for Valcyte - Possible overdose in pediatric patients - http://bit.ly/9zTGIc
Roche - IMPACT study shows longer Valcyte treatment provides better protection against cytomegalovirus (CMV) disease
roche.com — “Roche - IMPACT study shows longer Valcyte treatment provides better protection against cytomegalovirus (CMV) disease” View full resource at roche.com
Most Recently Shared on June 1, 2009 at 6:42 pm By:
IMPACT study shows longer Valcyte treatment provides better protection against cytomegalovirus (CMV) disease http://tinyurl.com/mnxkfs
IMPACT Study Showed Longer Valcyte (valganciclovir hydrochloride tablets) Treatment Demonstrated Better Protection Against Cytomegalovirus (CMV) Disease One Year Post-Transplant
newswise.com — “New Phase III study results presented for the first time today at the ninth annual American Transplant Congress 2009 (ATC) demonstrate that doubling the duration of preventive therapy ("prophylaxis') with Valcyte (oral valganciclovir) significantly reduced the incidence of CMV disease by 56% in high-risk kidney transplant patients within the first year post-transplant.” View full resource at newswise.com
Most Recently Shared on June 1, 2009 at 7:54 pm By:
IMPACT Study Showed Longer Valcyte (valganciclovir hydrochloride tablets) Treatment Demonstrated Better Protecti.. http://bit.ly/A52by
Health Tip: Nap to Feel More Rested - Drugs.com MedNews
drugs.com — “Our careers and busy lifestyles are leaving many of us sleep deprived. The National Sleep Foundation says there s nothing wrong with a daily nap to help you fee” View full resource at drugs.com
Most Recently Shared on September 20, 2010 at 2:05 pm By:
Drugs and Devices OW OW Health
Health Tip: Nap to Feel More Rested: -- Our careers and busy lifestyles are leaving many of us sleep deprived... http://bit.ly/czSSUi #drug
Longer Antiviral Therapy Reduces Lung Transplant Complications - Drugs.com MedNews
drugs.com — “Extended antiviral treatment after a lung transplant may help prevent dangerous complications and organ rejection, a new study from Duke University Medical Cent” View full resource at drugs.com
Most Recently Shared on June 14, 2010 at 11:14 pm By:
Longer Antiviral Therapy Reduces Lung Transplant Complications - http://bit.ly/aose1y
Montana Gov Says Drug Companies Avoiding Taxes - Drugs.com MedNews
drugs.com — “From Associated Press (September 16, 2010) Montana Gov. Brian Schweitzer said new laws are needed to collect taxes on income that he says big drug companies are” View full resource at drugs.com
Most Recently Shared on September 16, 2010 at 7:38 pm By:
Drugs and Devices OW OW Health
Montana Gov Says Drug Companies Avoiding Taxes: From Associated Press (September 16, 2010) HELENA, Mont. -- ... http://bit.ly/dgT9H4 #drug
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
OncologyNurseAdvisor
Oncology Nurse Advisor offers clinical updates and evidence-based guidance to the oncology nurse community and includes regular coverage of a variety of topics.
-
MPR
eMPR.com provides up-to-date, concise drug information at the point-of-care.
-
Pediatric SuperSite
The official Twitter feed for the PediatricSuperSite, home of Infectious Diseases in Children and Pediatric Annals
Advertisement
